Post-transcriptional repression of FOXO1 by QKI results in low levels of FOXO1 expression in breast cancer cells

FANG YU1,2, LIANG JIN1, GUODONG YANG1, LIN JI3, FENG WANG2 and ZIFAN LU1

1Department of Biochemistry and Molecular Biology, The State Key Laboratory of Cancer Biology; and Departments of 2Nutrition and Food Hygiene, 3Toxicology, The Fourth Military Medical University, Xi’an 710032, P.R. China

Received September 24, 2013; Accepted November 12, 2013

DOI: 10.3892/or.2013.2957

Abstract. The RNA-binding protein Quaking (QKI) is known to be essential for embryonic development and postnatal myelination. Forkhead box O1 (FOXO1) is a critical tumor suppressor for cell proliferation control. Dysregulation of FOXO1 expression has been observed in a variety of cancers. In the present study, we demonstrated that QKI decreased FOXO1 mRNA expression at the post-transcriptional level. QKI was able to bind the 3’UTR of FOXO1 mRNA directly and decreased its mRNA stability. To determine whether QKI-mediated post-transcriptional repression of FOXO1 indeed plays a role in cancer cells, we first detected both QKI and FOXO1 expression in four breast cancer cell lines. FOXO1 expression was extremely low in these cell lines, whereas QKI expression was relatively high. Knockdown of QKI significantly restored FOXO1 expression. ATRA, an inducer of apoptosis or differentiation, dramatically enhanced FOXO1 expression while it repressed QKI expression. Importantly, the ATRA-induced increase in FOXO1 expression was dependent on QKI-mediated post-transcriptional regulation. Consistently, 5-FU, a widely used chemotherapeutic agent, increased FOXO1 expression via inhibition of QKI. In summary, our study provides initial evidence demonstrating that QKI-mediated repression of FOXO1 may be one of the factors contributing to the oncogenesis and progression of breast carcinoma, which suggests that targeting QKI may serve as a novel strategy to sensitize breast cancers to chemotherapy.

Introduction

Quaking (QKI) is a KH-type RNA-binding protein encoded by the quaking (qk) locus (1). There are three isoforms of QKI, namely QKI-5, QKI-6 and QKI-7 (2,3). QKI-5 is the only nuclear isoform and shuttles between the nucleus and the cytoplasm, whereas QKI-6 and QKI-7 are localized in the cytoplasm (4,5). As an RNA-binding protein, QKI post-transcriptionally regulates the mRNA stability, translation efficiency or RNA transportation of target genes via specifically binding to the cis-elements within the 3’-untranslated region (3’UTR) (6-10). Among these targets, MAG and MBP, which are essential for postnatal myelination are well characterized. Overexpression of QKI-5 caused MBP mRNA retention in the nucleus, resulting in a reduction in its protein level and defects in myelination development (10,11).

In adult mammals, qki mRNAs can be detected in tissues, such as the heart, skeletal, lung, testes and immune cells in addition to the central nervous system (CNS) (9,12-15). In a search for putative RNA targets recognized by QKI, a bipartite consensus sequence ACUAAY-N(1-20)-UAAY was defined as a QKI response element (QRE), and 1,430 putative mRNA targets were identified by bioinformatic analysis (16). Thirteen percent were found to be associated with cell proliferation and cell cycle regulation. Among them, forkhead box O1 (FOXO1) appeared to be an appealing candidate due to its potent roles in regulating the cell cycle, apoptosis, stem cells and the aging process (17-23). Low and even undetectable FOXO1 expression has been observed in prostate, breast and colon cancers, suggesting its tumor-suppressor role (24-29). Nevertheless, the molecular mechanism for the aberrant expression of FOXO1 in those cancers remains to be elucidated.

In the present study, we provide initial evidence showing that QKI-5 repressed FOXO1 expression via decreasing its mRNA stability. ATRA and 5-FU increased FOXO1 expression at the post-transcriptional level through inhibition of QKI. Based on the findings, we suggest that targeting QKI may provide a new insight into novel therapies for the treatment of breast cancers.

Materials and methods

Cell culture and reagents. Human breast carcinoma cell lines, MCF-7, T47-D, MDA-MB-231 and SKBR-3, were cultured in Dulbecco's modified Eagle's medium (low glucose, Gibco, UK) supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 100 µg/ml streptomycin, and 2 mM L-glutamine at 37°C in a humidified atmosphere of 5% CO₂. ATRA (Sigma,
St. Louis, MO, USA) was dissolved in ethanol at the concentration of 10^{-3} mol/l as a stock. 5-FU (Sigma) was dissolved in DMSO at the concentration of 5 mg/ml as a stock and maintained at -20°C. Transcription inhibitor actinomycin D (Sigma) was dissolved in DMSO at the concentration of 5 mg/ml.

Plasmids, siRNAs and oligonucleotides. The FOXO1 3’UTR sequence containing three QKI response elements (QREs) corresponding to base pairs 3275-3279, 3337-3341 and 5298-5302 (wild-type, denoted pGL3-F) or its 3’UTR sequence with deleted QREs (mutant, denoted pGL3-FM) were amplified from MCF-7 cDNA and cloned into our previously recombined pGL3 vector with EcoRI, EcoRV, PstI inserted downstream of the XbaI site. pcDNA3.1(-)-flag-QKI-5 was kindly provided by Professor Feng Yue (Emory University, Atlanta, GA). Stealth™ siRNAs targeting QKI were synthesized by Invitrogen (Invitrogen Life Technologies, Carlsbad, CA, USA) and were dissolved in DEPC-treated H2O at a concentration of 20 pmol/µl as a stock.

Adenovirus. Recombinant adenoviruses expressing flag-tagged QKI-5 were generated using the AdEasy system (MP Biomedicals, Inc., Solon, OH, USA) according to the manufacturer’s instructions. MCF-7 cells were infected with the adenovirus-expressing vectors for 2 h and subsequently cultured for 24 h before being harvested.

RT-PCR. Following the indicated treatments, cells were harvested for isolation of RNA using TRIzol reagent (Invitrogen) according to the manufacturer’s instructions. First-strand cDNA synthesis was performed using random primers catalyzed by murine leukemia virus (M-MLV) reverse transcriptase. PCR conditions were as follows: 95°C for 5 min followed by 25 cycles of 95°C for 20 sec, 55°C for 20 sec, and 72°C for 30 sec. The primers for amplification were: QKI-1, sense 5’-atacagcctgcct-3’ and antisense 5’-tcacagtaacctgctg-3’; FOXO1, sense 5’-atacagcctgcct-3’ and antisense 5’-gacgccgctgcctg-3’; β-actin, sense 5’-gaa atcttgccacaccatc-3’ and antisense 5’-ggccggactcgtcatactc-3’.

Western blotting. Following the indicated treatments, cells were harvested and lysed in RIPA buffer containing 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate and 50 mM NaF. One tablet of protease inhibitor mixture (Complete Mini, Roche Applied Science, Burgess Hill, UK) was added just prior to use. Then 100 µg of the protein lysates was separated by 12% SDS-PAGE and transferred onto nitrocellulose membranes. After blocking in a 5% non-fat dried milk solution in washing buffer containing 10 mMol/l Tris (pH 7.5), 50 mMol/l NaCl and 0.2% Tween-20 (TBST), membranes were incubated overnight at 4°C with rabbit polyclonal anti-QKI (1:1,500; produced by our laboratory), anti-FOXO1 (1:2,500; Abcam, Cambridge, UK) and mouse polyclonal anti-α-tubulin (1:1,000; Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibodies. After being washed three times with TBST, the membranes were incubated for 1 h with horseradish peroxidase-coupled secondary antibodies (1:1,000 dilution; Santa Cruz Biotechnology) at room temperature. Signals were detected with the ECL kit (Amersham Pharmacia Biotech, Amersham, UK). The scanned images were quantified using Kodak Digital Science one-dimensional software (Eastman Kodak Co., New Haven, CT, USA).

Reporter gene assay. To detect the interaction between FOXO1 3’UTR and QKI-5, HEK-293 cells were seeded in 24-well plates and transfected with 400 ng of pGL3-F or pGL3-FM in combination with increased doses of pcDNA3.1-QKI-5, respectively. Cells were cotransfected with 50 ng of pBIND (a plasmid constitutively expressing Renilla luciferase) to normalize for the transfection efficiency. After 24 h of transfection, cells were lysed using passive lysis buffer and analyzed for firefly and Renilla luciferase activities using the Dual-Luciferase Reagent Assay kit (Promega, Madison, WI, USA) according to the manufacturer’s instructions.

Real-time PCR assay for FOXO1 mRNA decay. To analyze the stability of FOXO1 mRNA, transcription inhibitor actinomycin D (2 µg/ml) was added to the MCF-7 cells with the indicated treatment to stop further transcription. At the times indicated, total RNA was harvested using TRIzol reagent (Invitrogen). First-strand cDNA synthesis was performed using random primers catalyzed by murine leukemia virus (M-MLV) reverse transcriptase. Real-time PCR was performed with the SYBR® Premix Ex Taq™ (Takara Biotechnology, Dalian, China) in 25 µl reactions using ABI PRISM® 7500 Real-Time PCR System (Applied Biosystems, Grand Island, NY, USA). The primers for amplification were: FOXO1, sense 5’-cacaactgtg tcaagacaagc-3’ and antisense 5’-tctctctgcctgtcact-3’. The reactions were amplified for 40 cycles of 95°C for 5 sec and 60°C for 34 sec with predenaturation at 95°C for 30 sec. FOXO1 mRNA relative abundance was determined by normalizing to β-actin using the ΔC_T method, where C_T is the threshold cycle. The relative amount of FOXO1 mRNA without actinomycin D treatment was set to 100%.

RNA immunoprecipitation. MCF-7 cells were seeded in 100-mm dishes and transfected with recombinant adenoviruses expressing flag-tagged QKI-5 for 24 h. After protein-RNA crosslinking with 1% formaldehyde, cells were lysed in a buffer containing 10 mM HEPES (pH 7.9), 1.5 mM MgCl_2, 10 mM KCl, 0.5 mM DTT, 0.1% NP-40, 50 mM NaF, 10 mM Na_2VO_4, 10 mM sodium pyrophosphate, 50 mM sodium glycerol phosphate, 10 mM okadaic acid, 0.2% VRG, 100 U/ml RNASin and 1/25 v/v Complete EDTA-free protease inhibitor cocktail. The lysed cells were centrifuged at 12,000 x g for 10 min at 4°C. The supernatants were pre-cleaned for 60 min at 4°C by using 5 µl of Protein-A Sepharose beads (BD Biosciences, San Jose, CA, USA). After centrifugation, the supernatant was incubated with 30 µg of unrelated antibody (IgG, Sigma) or anti-flag at 4°C for 60 min. After incubation, 5 µl of protein-A Sepharose beads was added to all tubes and incubated for a further 60 min at 4°C. The tubes were centrifuged at 12,000 x g for 5 min, and the precipitated beads were washed with lysis buffer three times. The RNA in the immunoprecipitated complex and the RNA in the previously saved input fraction were released by reversing the cross-linking at 65°C for 2 h with 200 mM NaCl and 20 µg of proteinase K. The RNA was extracted as described above. Specific primers used to detect the presence of FOXO1 mRNAs were...
synthesized as follows: sense 5'-ttgttacatagtcagcttg-3' and
antisense 5'-tcactttcctgcccaaccag-3'. PCR conditions were:
95˚C for 5 min followed by 25 cycles of 95˚C for 15 sec, 55˚C
for 20 sec, and 72˚C for 1 min. All experiments described in
this study were performed in triplicate.

Statistical analysis. Data are expressed as mean ± SD from
three independent experiments. Statistical analysis was
performed using Student's t test to assess the differences
between the experimental groups. p<0.05 was considered to
indicate a statistically significant result.

Results

FOXO1 as a potential target of QKI. Due to limited informa-
tion concerning the function of QKI-5 outside the CNS system,
seeking for and verifying potential target genes may be an
efficient way to research the function of QKI-5. We selected
multiple potential targets of QKI, which are closely related to
cell cycle regulation, from the 1430 target genes identified by
Galarneau and Richard (16). Among them, FOXO1 was found
to be the most significant.

Bioinformatics analysis revealed that FOXO1 3'UTR
contained three conserved QREs (Fig. 1A). To test whether
FOXO1 is a target of QKI, two constructs with FOXO1 3'UTR
downstream of firefly luciferase in the pGL3 vector were
included. pGL3-F harbored the wild-type QRE while mutant
FOXO1 3'UTR (pGL3-FM) had none of the three QREs. As
shown in Fig. 1B, the luciferase activities of pGL3-F were grad-
ually reduced by QKI in a dose-dependent manner, whereas
that of GL3-FM was rarely changed by QKI. On the basis of the
above observations, we hypothesized that QKI may mediate a
negative regulation of FOXO1.

In order to detect the in vivo interaction between QKI
and FOXO1 3'UTR, an RNA co-immunoprecipitation
experiment was performed. MCF-7 cells were transfected with
pcDNA3.1-QKI-5 vector in combination with increasing doses of
pcDNA3.1-QKI-5 (50, 100 and 200 ng), respectively (n≥3). Luciferase activity was measured as described in Materials and methods. *p<0.05 by standard t-test.

To verify the negative regulation of FOXO1 by QKI,
small interfering RNA-mediated specific knockdown of QKI
increased the mRNA and protein levels of FOXO1, whereas
overexpression of QKI inhibited FOXO1 expression (Fig. 1D).

QKI decreases the mRNA stability of FOXO1. As QKI reduced
FOXO1 mRNA level to a great extent, it is reasonable to deduce
YU et al.: POST-TRANSCRIPTIONAL REGULATION OF FOXO1 BY QKI IN BREAST CANCER CELLS

that QKI, as an RNA binding protein, may regulate the mRNA stability of FOXO1. To test this, actinomycin D, a transcription inhibitor, was used to block the transcription initiation in cells transfected with negative control (siCon) and QKI siRNA (siQKI). Cells were harvested at different time points, and real-time PCR was employed to determine the decaying rate of FOXO1 mRNA. As shown in Fig. 2, the half-life of FOXO1 mRNA was 3.02 h in siCon cells, whereas it was prolonged to 6 h in siQKI cells. These data suggest that QKI destabilizes FOXO1 mRNA.

**Inverse expression of QKI and FOXO1 in breast cancer cell lines.** Strong evidence indicates that FOXO1 expression is extremely low and even undetectable in several types of cancers, including breast, prostate and endometrial cancers (24-29). To determine whether RNA binding protein QKI is responsible for the aberrant expression of FOXO1 in breast cancers, QKI and FOXO1 expression was detected in a panel of breast cancer cell lines. Consistent with previous findings, the FOXO1 expression level in the four cell lines was extremely low, with trace expression in MDA-MB-231, T47-D and SKBR-3 cells (Fig. 3). In sharp contrast, the expression of QKI was extremely high in these cells (Fig. 3). Furthermore, knockdown of QKI resulted in a significant increase in endogenous FOXO1 expression in these cell lines (Fig. 3). Our data suggest that negative regulation of FOXO1 by QKI may serve as one of the molecular mechanisms contributing to the low expression of FOXO1 in breast cancer cells.

**Upregulation of FOXO1 by ATRA or 5-FU is dependent on QKI.**

ATRA is capable of inhibiting cell proliferation, inducing cell cycle arrest and cell differentiation (30-34). Dysregulation of FOXO1 expression has been observed to decrease the sensitivity of various carcinoma cells to differentiation and apoptosis inducers (24,26,35-37). To evaluate whether QKI-mediated post-transcriptional repression of FOXO1 indeed plays a role in cancer cells, we detected the expression pattern of QKI and FOXO1 following ATRA treatment. FOXO1 expression showed a dramatic decrease upon ATRA induction, whereas FOXO1 expression was gradually increased, exhibiting a time-dependent trend (Fig. 4A, upper and lower panel). To ascertain whether enhanced FOXO1 expression by ATRA is dependent on QKI, pGL3-F and pGL3-FM plasmids were transfected, and the luciferase activities were determined following ATRA treatment. As expected, upon ATRA induction, the luciferase activities of FOXO1 3'UTR were gradually induced almost 50% (Fig. 4B). However, the luciferase activities of pGL3-FM were rarely changed (Fig. 4B). Furthermore, ATRA induced a marked increase in luciferase activities of FOXO1 3'UTR in siQKI cells compared to the siCon group (Fig. 4C). The above data indicate that QKI-mediated post-transcriptional regulation is indeed responsible for enhanced FOXO1 expression by ATRA induction.

To ascertain whether the post-transcriptional regulation of FOXO1 by QKI is not ATRA-specific, MCF-7 and MDA-MB-231 cells were treated with 5-FU. As shown in Fig. 5A and C, 5-FU induced FOXO1 expression whereas it inhibited QKI expression in both cell lines. Moreover, knockdown of QKI dramatically increased the luciferase activities of FOXO1 3'UTR upon 5-FU treatment (Fig. 5B and D), indicating that 5-FU enhances FOXO1 expression at the post-transcriptional level through inhibition of QKI expression.

**Discussion**

Previous studies have shown that QKI is an RNA-binding protein known to be important for myelination in the central nervous system (CNS) and peripheral nervous system, through regulating mRNA stability, translation, splicing and cytoplasmic/nuclear localization of target genes (1,4,6,8,10,13,38). In addition, QKI was previously found to bind p53 3'UTR
Figure 4. Enhanced FOXO1 expression by ATRA is dependent on QKI. (A) Inverse expression of QKI and FOXO1 upon ATRA induction. MCF-7 cells were treated with ATRA for different time points. RT-PCR and western blotting were executed to detect the mRNA and protein levels of QKI and FOXO1. *p<0.05. (B) Post-transcriptional regulation of FOXO1 by ATRA was detected by luciferase reporter gene assay. MCF-7 cells were seeded in 24-well plates and transfected with 800 ng of pGL3-F or pGL3-FM for 24 h followed by ATRA treatment. *p<0.05. (C) MCF-7 cells were seeded in 24-well plates and cotransfected with siCon+pGL3-F or siQKI+pGL3-F for 24 h followed by ATRA treatment. Luciferase activity was measured as described above. Data are expressed as means ± SD of at least three independent experiments. Student’s t-test was applied for analysis of significant difference. *p<0.05 compared to the group without ATRA treatment. #p<0.05 compared to the siCon group.

Figure 5. 5-FU increases FOXO1 expression via repressing QKI. Expression of QKI and FOXO1 upon 5-FU treatment was detected in MCF-7 (A) and MDA-MB-231 (B) cells. Both cell lines were treated with 5-FU (5 µg/ml), and mRNA levels were determined by RT-PCR. *p<0.05. Post-transcriptional regulation of FOXO1 by 5-FU was detected by luciferase reporter gene assay in MCF-7 (C) and MDA-MB-231 (D) cells. Both cell lines were seeded in 24-well plates and cotransfected with siCon+pGL3-F or siQKI+pGL3-F for 24 h followed by 5-FU treatment (5 µg/ml). Luciferase activity was measured as described above. Data are expressed as means ± SD of at least three independent experiments. Student’s t-test was applied for analysis of significant difference. *p<0.05 compared to the group without 5-FU treatment. #p<0.05 compared to the siCon group.
and inhibit its translation (39). Due to the limited information concerning QKI-5 function outside the CNS system, seeking for and verifying potential target genes may be an efficient way to elucidate the function of QKI-5.

FOXI1 was an appealing candidate among thousands of targets due to its diverse roles in controlling cell cycle, apoptosis, stem cells and the aging process (17-23,27). Previous studies found that FOXO1 function was closely related with its phosphorylation and acetylation modification which determined its transcriptional activity (40-44). Recent studies found that microRNAs, such as miR-96 and miR-370, downregulated FOXO1 expression (28,29). Our current data demonstrated that QKI, an RNA-binding protein, repressed the expression of FOXO1 via decreasing its mRNA stability (Figs. 1 and 2). Our study, for the first time, elucidated the detailed molecular mechanism by which FOXO1 mRNA was regulated at the post-transcriptional level.

FOXI1 is a critical tumor suppressor, and its expression is often dysregulated in cancers, such as breast, bladder, prostate and endometrial cancers (24-29). Our study observed that QKI and FOXO1 were inversely expressed in breast cancer cells, and the low expression level of FOXO1 mRNA could be enhanced by knockdown of QKI (Figs. 1D and 3), elucidating a novel mechanism of how FOXO1 is aberrantly expressed in breast cancer. As a critical transcription factor, FOXO1 orchestrated regulates genes involved in cell proliferation, apoptotic response, cell cycle checkpoints and cellular metabolism (17,21,23). We hypothesized that a low level of FOXO1 expression may make these cancers resistant to apoptosis- or differentiation-inducing agents. Of note, ATRA and 5-FU significantly induced an increase in FOXO1 expression through inhibition of QKI (Figs. 4 and 5). Our further study will disclose whether QKI-mediated post-transcription repression of FOXO1 is involved in ATRA or 5-FU-mediated effects and knockdown of QKI indeed sensitizes breast cancer cells to those agents.

In contrast to our previous research in which QKI functioned as a tumor suppressor in colonic epithelial cells and gastric cancer (45,46), the present study suggests that QKI may function as an oncogene in breast cancer. The reason for this discrepancy may be due to the cell-context dependent role of QKI. As we know, QKI is an RNA-binding protein belonging to the STAR family, and its function is dependent on the accessibility of its targets and the cellular environment. Thus, it is reasonable to suggest that QKI functions differently in different cells.

In summary, our study provides initial evidence that dysregulation of FOXO1 by QKI via post-transcriptional inhibition may be one of the factors contributing to the oncogenesis and progression of breast carcinoma. Thus, targeting QKI may serve as a novel strategy to sensitize breast cancers to chemotherapy and/or radiotherapy.

Acknowledgements

This study was supported by the National Science Fund of China (NSF: 31000520; NSF: 30470387; NSF: 30570396; NSF: C030200303) and Program for Changjiang Scholars and Innovative Research Team in the University (IRT0459).

References


